OncoMatch/Clinical Trials/NCT06225310
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Is NCT06225310 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Selinexor and Ruxolitinib for multiple myeloma in relapse.
Treatment: Selinexor · Ruxolitinib · Methylprednisolone — Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: anti-CD38 antibody
Received an Anti-CD38 antibody
Must have received: immunomodulatory agent
Received an Immunomodulatory agent (IMiD)
Must have received: proteasome inhibitor
Received a Proteasome inhibitor (PI)
Cannot have received: JAK inhibitor (ruxolitinib)
Patients who had prior exposure to ruxolitinib
Cannot have received: XPO1 inhibitor (selinexor)
Patients who had prior exposure to selinexor
Lab requirements
Blood counts
WBC ≥1500/mm3, ANC ≥1000/mm3, hemoglobin ≥8.5 g/dL, platelet count ≥75,000/mm3 (<50% BM plasma cells) or ≥50,000/mm3 (≥50% BM plasma cells)
Kidney function
estimated CrCl > 60 mL/min (Cockcroft and Gault formula)
Liver function
Total bilirubin < 1.5 × ULN (except Gilbert's syndrome < 3 × ULN), AST and ALT normal to < 2 × ULN
Adequate hepatic function within 14 days prior to C1D1: Total bilirubin < 1.5 × ULN (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 × ULN), and AST and ALT normal to < 2 × ULN. Adequate renal function within 14 days prior to C1D1 as determined by OR estimated CrCl of > 60 mL/min, calculated using the Cockcroft and Gault formula. Adequate hematopoietic function within 14 days prior to C1D1: total WBC count ≥1500/mm3, ANC ≥1000/mm3, hemoglobin ≥8.5 g/dL and platelet count ≥75,000/mm3 (<50% BM nucleated cells are plasma cells) or ≥50,000/mm3 (≥50% BM nucleated cells are plasma cells).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Berenson Cancer Center · West Hollywood, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify